Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

February 28, 2022

Targeted therapies, specifically those agents directed at mutated proteins and aberrant protein-to-protein interactions, have been shown to improve survival among patients with relapsed or refractory acute myeloid leukemia.

February 24, 2022

The addition of atezolizumab to neoadjuvant gemcitabine and cisplatin generated a high rate of non–muscle-invasive downstaging following radical cystectomy, which correlated with improved relapse-free survival and overall survival in patients with muscle-invasive bladder cancer, according to data from a phase 2 trial.

February 21, 2022

Neil M. Iyengar, MD, discusses the use of fam-trastuzumab deruxtecan-nxki in HER2-low breast cancer.

February 19, 2022

Treatment with lenvatinib plus pembrolizumab was associated with a clinical benefit in advanced renal cell carcinoma, regardless of a patient’s biomarker status.

February 19, 2022

OncLive® speaks with Drs. Jonathan Rosenberg and Guru Sonpavde on the groundbreaking research being presented in bladder cancer.

February 19, 2022

The addition of olaparib to durvalumab did not result in a significant prolongation in progression-free survival compared with durvalumab alone in patients with previously untreated, platinum-ineligible metastatic urothelial carcinoma.

February 11, 2022

Saad Z. Usmani, MD, MBA, FACP, shares key takeaways from presentations given during the meeting on the evolving paradigms of frontline, early relapsed, and late relapsed multiple myeloma, the current role of bispecific antibodies and CAR T-cell therapy, and emerging immunotherapies and also trials in progress in the space.

February 11, 2022

Geoffrey Y. Ku, MD, medical oncologist, discusses the efficacy of zanidatamab plus standard chemotherapy in patients with HER2-positive gastroesophageal adenocarcinoma in the ongoing phase 2 ZW25-201 trial.

February 04, 2022

Neha S. Korde, MD, hematologist, Memorial Sloan Kettering Cancer Center, discusses key updates to the ​phase 3 Cassiopeia study (NCT02541383) in multiple myeloma.

February 02, 2022

Saad Z. Usmani, MD, MBA, FACP, discusses emerging treatment strategies in late relapsed multiple myeloma.

February 02, 2022

William D. Tap, MD, discusses developing treatment opportunities in soft tissue sarcomas.

January 18, 2022

The combination of durvalumab and tremelimumab demonstrated a significant improvement in overall survival vs sorafenib as frontline therapy in patients with unresectable hepatocellular carcinoma, according to findings from the phase 3 HIMALAYA trial.

January 11, 2022

Michael J. Morris, MD, discusses logistical challenges of utilizing Lutetium 177 PSMA-617 in prostate cancer.

December 22, 2021

Daniel C. Danila, MD, discusses ​the rationale for examining immunotherapy in early-stage prostate cancer.

December 19, 2021

Malin Hultcrantz, MD, PhD, discusses the efficacy of belantamab mafodotin, as well as standard management for common adverse effects associated with the treatment.

December 13, 2021

The combination of duvelisib plus romidepsin was shown to be highly active in patients with relapsed/peripheral T-cell lymphoma, according to final results from the dose expansion stage of a phase 1 trial.

December 13, 2021

The addition of ublituximab and umbralisib to ibrutinib produced deep remissions with favorable tolerability in patients with chronic lymphocytic leukemia who previously received ibrutinib and still had detectable minimal residual disease.

December 07, 2021

The highest incidence of lymphedema observed was among the Black women with a 24-month lymphedema rate of 39.4%.

December 06, 2021

Meghan Thompson, MD, discusses the results from the use of pirtobrutinib in the phase 1/2 BRUIN study, as well as upcoming research efforts in the population of patients with Richter transformation.

November 19, 2021

Diane Reidy-Lagunes, MD, unpacked recent updates in neuroendocrine tumors.